Literature DB >> 16496229

Etiopathogenesis of primary sclerosing cholangitis.

Christine A O'Mahony1, John M Vierling.   

Abstract

The etiopathogenesis of primary sclerosing cholangitis (PSC) remains undefined. Immunopathogenetic mechanisms appear to be involved, based on human leukocyte antigen complex susceptibility associations, existence of multiple autoantibodies, and presence of inflammatory bowel disease in > 75% of patients. PSC may represent an autoimmune disease with atypical features or an immune-mediated inflammatory disease, similar to inflammatory bowel disease itself. Immunogenetic susceptibility is closely linked to ligands for innate immune cells and capacity for sustained production of proinflammatory cytokines. Immunopathogenesis involves a multistep process initiated by the activation of cholangiocyte by bacterial pathogen-associated molecular patterns (stimuli of innate immunity) and proinflammatory cytokines in conjunction with aberrant expression of gut-specific chemokines and endothelial cell adhesion molecules in the liver. After recruitment of gut-primed memory T cells into the portal tracts and peribiliary space, additional mechanisms produce focal, fibrous, obliterative lesions. Progressive periductal fibrosis, chronic inflammation, and ischemic atrophy of biliary epithelia result in ductopenia, cholestasis, and obstructive strictures, culminating in secondary biliary cirrhosis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16496229     DOI: 10.1055/s-2006-933559

Source DB:  PubMed          Journal:  Semin Liver Dis        ISSN: 0272-8087            Impact factor:   6.115


  38 in total

1.  Curcumin improves sclerosing cholangitis in Mdr2-/- mice by inhibition of cholangiocyte inflammatory response and portal myofibroblast proliferation.

Authors:  Anna Baghdasaryan; Thierry Claudel; Astrid Kosters; Judith Gumhold; Dagmar Silbert; Andrea Thüringer; Katharina Leski; Peter Fickert; Saul J Karpen; Michael Trauner
Journal:  Gut       Date:  2010-04       Impact factor: 23.059

Review 2.  Genetic epidemiology of primary sclerosing cholangitis.

Authors:  Tom-H Karlsen; Erik Schrumpf; Kirsten-Muri Boberg
Journal:  World J Gastroenterol       Date:  2007-11-07       Impact factor: 5.742

Review 3.  Primary sclerosing cholangitis--approach to diagnosis.

Authors:  Ian L Steele; Cynthia Levy; Keith D Lindor
Journal:  MedGenMed       Date:  2007-04-25

Review 4.  Autoantibodies in primary sclerosing cholangitis.

Authors:  Johannes-Roksund Hov; Kirsten-Muri Boberg; Tom-H Karlsen
Journal:  World J Gastroenterol       Date:  2008-06-28       Impact factor: 5.742

Review 5.  Etiopathogenesis of primary sclerosing cholangitis.

Authors:  Roger Chapman; Sue Cullen
Journal:  World J Gastroenterol       Date:  2008-06-07       Impact factor: 5.742

Review 6.  Primary sclerosing cholangitis: diagnosis, prognosis, and management.

Authors:  Siddharth Singh; Jayant A Talwalkar
Journal:  Clin Gastroenterol Hepatol       Date:  2013-02-27       Impact factor: 11.382

Review 7.  Preemptive surgery for premalignant foregut lesions.

Authors:  Rohit R Sharma; Mark J London; Laura L Magenta; Mitchell C Posner; Kevin K Roggin
Journal:  J Gastrointest Surg       Date:  2009-06-10       Impact factor: 3.452

8.  Mutational characterization of the bile acid receptor TGR5 in primary sclerosing cholangitis.

Authors:  Johannes R Hov; Verena Keitel; Jon K Laerdahl; Lina Spomer; Eva Ellinghaus; Abdou ElSharawy; Espen Melum; Kirsten M Boberg; Thomas Manke; Tobias Balschun; Christoph Schramm; Annika Bergquist; Tobias Weismüller; Daniel Gotthardt; Christian Rust; Liesbet Henckaerts; Clive M Onnie; Rinse K Weersma; Martina Sterneck; Andreas Teufel; Heiko Runz; Adolf Stiehl; Cyriel Y Ponsioen; Cisca Wijmenga; Morten H Vatn; Pieter C F Stokkers; Severine Vermeire; Christopher G Mathew; Benedicte A Lie; Ulrich Beuers; Michael P Manns; Stefan Schreiber; Erik Schrumpf; Dieter Häussinger; Andre Franke; Tom H Karlsen
Journal:  PLoS One       Date:  2010-08-25       Impact factor: 3.240

Review 9.  Primary sclerosing cholangitis and the microbiota: current knowledge and perspectives on etiopathogenesis and emerging therapies.

Authors:  James H Tabibian; Steven P O'Hara; Keith D Lindor
Journal:  Scand J Gastroenterol       Date:  2014-07-03       Impact factor: 2.423

Review 10.  The immunobiology of primary sclerosing cholangitis.

Authors:  Jonathan H Aron; Christopher L Bowlus
Journal:  Semin Immunopathol       Date:  2009-05-26       Impact factor: 9.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.